Tacrolimus (Auritec)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameTacrolimus (Auritec)
Drug Alias NameSustained Release Injectable Tacrolimus (Auritec)SR-TAC
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCalcineurin inhibitorsBone morphogenetic protein receptor type-2 agonistsT cell activation inhibitors +[5] 
TargetsCalcineurinBone morphogenetic protein receptor type-2Cytokines
Therapy Area/IndicationsRejection of organ transplantationPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAuritec Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAuritec Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A